Envista Holdings Corp
Envista Holdings Corp is a U.S.-based dental products company built around more than 30 brands, including Nobel Biocare, Ormco, DEXIS, and Kerr. It sells implants, orthodontics, imaging, restorative, endodontic, rotary, and infection-prevention products used by dental professionals to diagnose, treat, and prevent oral disease.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDental implant solutions and orthodontic products, including clear aligners and related treatment workflows.
Diagnostic equipment, imaging, software, and consumable dental supplies used in daily practice.
Customers
Envista sells primarily to dental specialists and general practitioners, but its customer base also includes dental laboratories, DSOs, hygienists, oral surgeons, educational institutions, governments, and distributors. Demand is driven by clinical need, workflow efficiency, brand trust, and product performance across diagnosis, treatment, and prevention.
Orthodontists, implantologists, periodontists, and endodontists buy specialty systems and advanced clinical products for complex procedures.
General practitioners buy imaging, restorative, endodontic, and consumable products for routine diagnosis and treatment.
Dental service organizations buy across multiple categories to standardize products, pricing, and workflows across practices.
Third-party distributors, especially Henry Schein, resell Envista products and are important for market access and scale.
Labs, schools, medical entities, and governments buy specialized equipment and supplies for training, care delivery, and procurement.
Strategy
Envista is focused on portfolio innovation, commercial expansion, and continued investment in its implant and orthodontic platforms, especially Spark clear aligners. Management also emphasizes acquisitions, cost reduction, and manufacturing productivity to fund growth while improving margins.
Aligners are a key growth engine and benefit from deferred revenue timing and manufacturing scale.
New products and technologies support pricing power, customer retention, and category expansion.
These markets offer penetration upside and diversify growth beyond mature regions.
M&A can add technologies, brands, and geographic reach if integration is successful.
Geography
Q2/2026Envista serves dental professionals in more than 130 countries, with sales concentrated in North America, Western Europe, and emerging markets. The company’s 2025 revenue mix shows North America as the largest region, while Europe and emerging markets are also meaningful, making foreign exchange, trade policy, and regional demand trends important to results.
Risks
Envista is exposed to cyclical dental demand, distributor concentration, and intense competition across fragmented product categories. It also faces foreign exchange, tariffs, trade policy, geopolitical disruption, and manufacturing concentration risks, while goodwill and intangible assets remain sensitive to impairment if growth or margins weaken.
- Distributor concentrationImpact: HighLikelihood: Medium
Henry Schein represented about 12% of 2025 sales and remains the largest channel partner.
Exposure: Channel sales and U.S./Canada distribution
- Demand weakness in key marketsImpact: HighLikelihood: Medium
Dental procedures and equipment purchases can slow when economic conditions soften.
Exposure - Goodwill and intangible impairmentImpact: HighLikelihood: Medium
Prior impairment charges show that valuation assumptions can change quickly if performance weakens.
Exposure - Trade policy and tariffsImpact: MediumLikelihood: Medium
Cross-border sourcing and manufacturing make the company sensitive to tariff changes and trade restrictions.
Exposure: Global supply chain and international sales
- Foreign exchange volatilityImpact: MediumLikelihood: Medium
A large share of revenue is outside the U.S., so currency moves affect reported sales and margins.
Exposure: Europe and emerging markets
Accounting
Judgemental itemsRevenue is recognized as performance obligations are satisfied, so timing can move sales between quarters.
Impact: Can materially affect quarterly growth and comparability
Large acquired asset balances depend on management assumptions about growth, margins, and discount rates.
Impact: Can create significant non-cash charges to earnings
Acquisitions add patents, technology, and customer relationships that are amortized over time.
Impact: Affects operating profit and reported margins
Management excludes acquisitions and currency effects to show underlying demand trends.
Impact: Useful for trend analysis but not a GAAP substitute
Similar listed companies
Publicly listed companies with a comparable business focus.
Enovis CORP
ENOV · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Enovis is a U.S.-based medical technology company focused on orthopedic and musculoskeletal care.
Envela Corp
ELA · Retail-Jewelry Stores
Envela Corp is a U.S.-based holding company operating through subsidiaries in recommerce and recycling.
ENvue Medical, Inc.
FEED · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Align Technology, Inc
ALGN · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Envoy Medical, Inc.
COCHW · Orthopedic, Prosthetic & Surgical Appliances & Supplies
DENTSPLY SIRONA Inc
XRAY · Dental Equipment & Supplies
Last updated: 24/09/2026